Geor Bakker

1.5k citations

21 papers · 299 indexed · h-index 11

Co-authors: Thérèse van Amelsvoort Oswald Bloemen Jan Booij Pradeep J. Nathan Alastair Brown Matthan W.A. Caan Claudia Vingerhoets John‐Paul Taylor
Topics: Neuroscience and Neuropharmacology Research (11 papers)Receptor Mechanisms and Signaling (10 papers)Schizophrenia research and treatment (5 papers)
Cited by: Cellular and Molecular Neuroscience Psychiatry and Mental health Biological Psychiatry
Journals: PLoS ONE Journal of Pharmacology and Experimental Therapeutics Psychological Medicine
Partner nations: Netherlands United Kingdom Australia

In The Last Decade

Geor Bakker

21 papers receiving 297 citations

Peers

Countries citing papers authored by Geor Bakker

Since Specialization

Citations

This map shows the geographic impact of Geor Bakker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geor Bakker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geor Bakker more than expected).

Fields of papers citing papers by Geor Bakker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geor Bakker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geor Bakker. The network helps show where Geor Bakker may publish in the future.

Co-authorship network of co-authors of Geor Bakker

This figure shows the co-authorship network connecting the top 25 collaborators of Geor Bakker. A scholar is included among the top collaborators of Geor Bakker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geor Bakker. Geor Bakker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Social Dysfunction and Neural Processing of Emotional Valence Across Depressive and Anxiety Disorders 2024 ·Depression and Anxiety ·(unknown),Geor Bakker,Tanja Su,(unknown),Laura Nawijn,Marie‐José van Tol,Nic J.A. van der Wee,Yolande A.L. Pijnenburg,Brenda W.J.H. Penninx	2
2	A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia 2023 ·Frontiers in Cellular Neuroscience ·Brian Dean,Geor Bakker,Hiroki R. Ueda,Andrew B. Tobin,Alastair Brown,Richard Kanaan	23
3	Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases? 2022 ·Frontiers in Pharmacology ·(unknown),Geor Bakker,Eugenia Sergeev,K.A. Bennett,Sophie J. Bradley	20
4	Effect of HTL0045725, a selective agonist of the orphan receptor GPR52, on kinase and transcription factor phosphorylation in striatal neurons 2022 ·Neuroscience Applied ·Eugenia Sergeev,(unknown),(unknown),K.A. Bennett,(unknown),(unknown),Geor Bakker,(unknown),(unknown),(unknown),(unknown),(unknown)	2
5	Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies 2021 ·Journal of Pharmacology and Experimental Therapeutics ·K.A. Bennett,Eugenia Sergeev,Cliona MacSweeney,Geor Bakker,Anne Cooper	3
6	Spatial Covariance of Cholinergic Muscarinic M₁/M₄ Receptors in Parkinson's Disease 2021 ·Movement Disorders ·Sean J. Colloby,Pradeep J. Nathan,Geor Bakker,Rachael A. Lawson,Alison J. Yarnall,David J. Burn,John T. O’Brien,John‐Paul Taylor	7
7	The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders 2020 ·NeuroImage Clinical ·Geor Bakker,Claudia Vingerhoets,Oswald Bloemen,Barbara J. Sahakian,Jan Booij,Matthan W.A. Caan,Thérèse van Amelsvoort	7
8	Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption 2020 ·Psychopharmacology ·Pradeep J. Nathan,Geor Bakker	5
9	MATLAB doesn't love me: an essay 2020 ·University of Groningen research database (University of Groningen / Centre for Information Technology) ·Tijs van der Storm,Geor Bakker	1
10	Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies 2020 ·Brain Communications ·Sean J. Colloby,Pradeep J. Nathan,Ian G. McKeith,Geor Bakker,John T. O’Brien,John‐Paul Taylor	10
11	Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders 2019 ·Drug Discovery Today ·Daniel Erskine,John‐Paul Taylor,Geor Bakker,Alastair Brown,Tim Tasker,Pradeep J. Nathan	38
12	Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study 2019 ·Psychiatry Research Neuroimaging ·Claudia Vingerhoets,Geor Bakker,Anouk Schrantee,(unknown),Oswald Bloemen,Liesbeth Reneman,Matthan W.A. Caan,Jan Booij,Thérèse van Amelsvoort	3
13	Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis 2018 ·NeuroImage Clinical ·Geor Bakker,Claudia Vingerhoets,(unknown),Matthan W.A. Caan,Oswald Bloemen,Jos Eersels,Jan Booij,Thérèse van Amelsvoort	36
14	The effect of the muscarinic M 1 receptor antagonist biperiden on cognition in medication free subjects with psychosis 2017 ·European Neuropsychopharmacology ·Claudia Vingerhoets,Geor Bakker,(unknown),Oswald Bloemen,Ya Wang,Raymond C. K. Chan,Jan Booij,Thérèse van Amelsvoort	15
15	Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis 2017 ·Psychiatry Research Neuroimaging ·Claudia Vingerhoets,Oswald Bloemen,Erik Boot,Geor Bakker,Mariken B. de Koning,Fabiana da Silva Alves,Jan Booij,Thérèse van Amelsvoort	8
16	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome 2016 ·PLoS ONE ·Geor Bakker,Matthan W.A. Caan,(unknown),(unknown),(unknown),Erik Boot,Dorien H. Nieman,Lieuwe de Haan,Oswald Bloemen,Jan Booij,Thérèse van Amelsvoort	20
17	Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis 2016 ·Psychological Medicine ·Geor Bakker,Matthan W.A. Caan,Renée S. Schluter,Oswald Bloemen,(unknown),Mariken B. de Koning,Erik Boot,(unknown),Dorien H. Nieman,Lieuwe de Haan,Jan Booij,Thérèse van Amelsvoort	20
18	¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁In Vivo 2015 ·Journal of Nuclear Medicine ·Geor Bakker,(unknown),(unknown),Kora de Bruin,Jos Eersels,Jan de Jong,(unknown),Bart P. F. Rutten,Susan L. DuBois,(unknown),Adrian J. Mogg,(unknown),Michael Crabtree,David Collier,Christian C. Felder,Vanessa Barth,Lisa M. Broad,Oswald Bloemen,Thérèse A. van Amelsvoort,Jan Booij	18
19	Dopaminergic modulation of the reward system in schizophrenia: A placebo-controlled dopamine depletion fMRI study 2013 ·European Neuropsychopharmacology ·Fabiana da Silva Alves,Geor Bakker,Nicole Schmitz,N. G. G. M. Abeling,Gregor Hasler,J. van der Meer,Aart J. Nederveen,Lieuwe de Haan,Don Linszen,Thérèse van Amelsvoort	23
20	Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What’s the Evidence? 2013 ·Frontiers in Psychiatry ·(unknown),Oswald Bloemen,Geor Bakker,Thérèse van Amelsvoort	33

About Geor Bakker

Geor Bakker is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Cognitive Neuroscience, having authored 21 papers that have together received 299 indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (10 papers) and Schizophrenia research and treatment (5 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (118 citations), Psychiatry and Mental health (94 citations) and Biological Psychiatry (14 citations). Geor Bakker has collaborated with scholars based in Netherlands, United Kingdom and Australia. Frequent co-authors include Thérèse van Amelsvoort, Oswald Bloemen, Jan Booij, Pradeep J. Nathan, Alastair Brown, Matthan W.A. Caan, Claudia Vingerhoets, John‐Paul Taylor, Tim Tasker and Daniel Erskine. Their work appears in journals such as PLoS ONE, Journal of Pharmacology and Experimental Therapeutics and Psychological Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact